Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study

DOI record: { "DOI": "10.7759/cureus.14933", "ISSN": [ "2168-8184" ], "URL": "http://dx.doi.org/10.7759/cureus.14933", "author": [ { "affiliation": [], "family": "Alam", "given": "Mohammud M", "sequence": "first" }, { "affiliation": [], "family": "Mahmud", "given": "Saborny", "sequence": "additional" }, { "affiliation": [], "family": "Aggarwal", "given": "Sandeep", "sequence": "additional" }, { "affiliation": [], "family": "Fathma", "given": "Sawsan", "sequence": "additional" }, { "affiliation": [], "family": "Al Mahi", "given": "Naim", "sequence": "additional" }, { "affiliation": [], "family": "Shibli", "given": "Mohammed S", "sequence": "additional" }, { "affiliation": [], "family": "Haque", "given": "Siddiqi M", "sequence": "additional" }, { "affiliation": [], "family": "Mahmud", "given": "Sharothy", "sequence": "additional" }, { "affiliation": [], "family": "Ahmed", "given": "Ziauddin", "sequence": "additional" } ], "container-title": "Cureus", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2021, 5, 10 ] ], "date-time": "2021-05-10T15:18:59Z", "timestamp": 1620659939000 }, "deposited": { "date-parts": [ [ 2024, 2, 9 ] ], "date-time": "2024-02-09T19:26:10Z", "timestamp": 1707506770000 }, "indexed": { "date-parts": [ [ 2024, 2, 10 ] ], "date-time": "2024-02-10T00:06:12Z", "timestamp": 1707523572364 }, "is-referenced-by-count": 5, "issued": { "date-parts": [ [ 2021, 5, 10 ] ] }, "language": "en", "link": [ { "URL": "https://www.cureus.com/articles/58640-clinical-impact-of-the-early-use-of-monoclonal-antibody-ly-cov555-bamlanivimab-on-mortality-and-hospitalization-among-elderly-nursing-home-patients-a-multicenter-retrospective-study", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.7759", "published": { "date-parts": [ [ 2021, 5, 10 ] ] }, "published-print": { "date-parts": [ [ 2021, 5, 10 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1056/NEJMe2002387", "article-title": "Covid-19 - navigating the uncharted", "author": "Fauci AS", "doi-asserted-by": "publisher", "journal-title": "N Engl J Med", "key": "ref1", "unstructured": "Fauci AS, Lane HC, Redfield RR. Covid-19 - navigating the uncharted. N Engl J Med. 2020, 382:1268-9. 10.1056/NEJMe2002387", "volume": "382", "year": "2020" }, { "key": "ref2", "unstructured": "COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. (2020). Accessed. April 5, 2021: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6." }, { "key": "ref3", "unstructured": "The New York Times. How many of these 68,000 deaths could have been avoided?. (2020). https.//www.nytimes.com/2020/09/05/opinion/sunday/coronavirus-nursing-homes-deaths.html." }, { "DOI": "10.1001/jamanetworkopen.2020.8857", "article-title": "Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial", "author": "Borba MGS", "doi-asserted-by": "publisher", "journal-title": "JAMA Netw Open", "key": "ref4", "unstructured": "Borba MGS, Val FFA, Sampaio VS, et al.. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020, 3:e208857. 10.1001/jamanetworkopen.2020.8857", "volume": "3", "year": "2020" }, { "DOI": "10.1001/jama.2020.16349", "article-title": "Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial", "author": "Spinner CD", "doi-asserted-by": "publisher", "journal-title": "JAMA", "key": "ref5", "unstructured": "Spinner CD, Gottlieb RL, Criner GJ, et al.. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial. JAMA. 2020, 324:1048-57. 10.1001/jama.2020.16349", "volume": "324", "year": "2020" }, { "DOI": "10.1016/j.ijid.2020.11.191", "article-title": "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness", "author": "Ahmed S", "doi-asserted-by": "publisher", "journal-title": "Int J Infect Dis", "key": "ref6", "unstructured": "Ahmed S, Karim MM, Ross AG, et al.. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021, 103:214-6. 10.1016/j.ijid.2020.11.191", "volume": "103", "year": "2021" }, { "DOI": "10.1101/2020.08.27.20183442", "article-title": "Tocilizumab in hospitalized patients with COVID-19 pneumonia [Preprint]", "author": "Rosas IO", "doi-asserted-by": "publisher", "journal-title": "MedRxiv", "key": "ref7", "unstructured": "Rosas IO, Bräu N, Waters M, et al.. Tocilizumab in hospitalized patients with COVID-19 pneumonia [Preprint]. MedRxiv. 2020, 10.1101/2020.08.27.20183442", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30361-5", "article-title": "On the use of corticosteroids for 2019-nCoV pneumonia", "author": "Shang L", "doi-asserted-by": "publisher", "journal-title": "Lancet", "key": "ref8", "unstructured": "Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020, 395:683-4. 10.1016/S0140-6736(20)30361-5", "volume": "395", "year": "2020" }, { "DOI": "10.1001/jama.2020.10044", "article-title": "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial", "author": "Li L", "doi-asserted-by": "publisher", "journal-title": "JAMA", "key": "ref9", "unstructured": "Li L, Zhang W, Hu Y, et al.. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020, 324:460-7. 10.1001/jama.2020.10044", "volume": "324", "year": "2020" }, { "DOI": "10.1101/2020.05.18.20066902", "article-title": "Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 patients: experience from case series of 54 patients in long-term care facilities [Preprint]", "author": "Ahmad I", "doi-asserted-by": "publisher", "journal-title": "MedRxiv", "key": "ref10", "unstructured": "Ahmad I, Alam M, Saadi R, et al.. Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 patients: experience from case series of 54 patients in long-term care facilities [Preprint]. MedRxiv. 2020, 10.1101/2020.05.18.20066902", "year": "2020" }, { "DOI": "10.7759/cureus.9658", "article-title": "Clinical outcomes of early treatment with doxycycline for 89 high-risk COVID-19 patients in long-term care facilities in New York", "author": "Alam MM", "doi-asserted-by": "publisher", "journal-title": "Cureus", "key": "ref11", "unstructured": "Alam MM, Mahmud S, Rahman MM, Simpson J, Aggarwal S, Ahmed Z. Clinical outcomes of early treatment with doxycycline for 89 high-risk COVID-19 patients in long-term care facilities in New York. Cureus. 2020, 12:e9658. 10.7759/cureus.9658", "volume": "12", "year": "2020" }, { "DOI": "10.1016/j.cell.2020.02.052", "article-title": "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", "author": "Hoffmann M", "doi-asserted-by": "publisher", "journal-title": "Cell", "key": "ref12", "unstructured": "Hoffmann M, Kleine-Weber H, Schroeder S, et al.. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020, 181:271-280.e8. 10.1016/j.cell.2020.02.052", "volume": "181", "year": "2020" }, { "DOI": "10.1126/science.abd0827", "article-title": "Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail", "author": "Hansen J", "doi-asserted-by": "publisher", "journal-title": "Science", "key": "ref13", "unstructured": "Hansen J, Baum A, Pascal KE, et al.. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020, 369:1010-4. 10.1126/science.abd0827", "volume": "369", "year": "2020" }, { "key": "ref14", "unstructured": "Regeneron. (2020). https.//investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-...." }, { "DOI": "10.1056/NEJMoa2029849", "article-title": "SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19", "author": "Chen P", "doi-asserted-by": "publisher", "journal-title": "N Engl J Med", "key": "ref15", "unstructured": "Chen P, Nirula A, Heller B, et al.. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021, 384:229-37. 10.1056/NEJMoa2029849", "volume": "384", "year": "2021" }, { "DOI": "10.1056/NEJMoa2035002", "article-title": "REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19", "author": "Weinreich DM", "doi-asserted-by": "publisher", "journal-title": "N Engl J Med", "key": "ref16", "unstructured": "Weinreich DM, Sivapalasingam S, Norton T, et al.. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021, 384:238-51. 10.1056/NEJMoa2035002", "volume": "384", "year": "2021" }, { "DOI": "10.1016/j.immuni.2020.05.002", "article-title": "Immunology of COVID-19: current state of the science", "author": "Vabret N", "doi-asserted-by": "publisher", "journal-title": "Immunity", "key": "ref17", "unstructured": "Vabret N, Britton GJ, Gruber C, et al.. Immunology of COVID-19: current state of the science. Immunity. 2020, 52:910-41. 10.1016/j.immuni.2020.05.002", "volume": "52", "year": "2020" }, { "DOI": "10.1093/nsr/nwaa041", "article-title": "Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients", "author": "Zhou Y", "doi-asserted-by": "publisher", "journal-title": "Natl Sci Rev", "key": "ref18", "unstructured": "Zhou Y, Fu B, Zheng X, et al.. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 2020, 7:nwaa041. 10.1093/nsr/nwaa041", "volume": "7", "year": "2020" }, { "DOI": "10.23812/CONTI-E", "article-title": "Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COV-19 or SARS-CoV-2): anti-inflammatory strategies", "author": "Conti P", "doi-asserted-by": "publisher", "journal-title": "J Biol Regul Homeost Agents", "key": "ref19", "unstructured": "Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COV-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020, 34:327-31. 10.23812/CONTI-E", "volume": "34", "year": "2020" }, { "DOI": "10.1016/S2352-3026(20)30145-9", "article-title": "Coagulation abnormalities and thrombosis in patients with COVID-19", "author": "Levi M", "doi-asserted-by": "publisher", "journal-title": "Lancet Haematol", "key": "ref20", "unstructured": "Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020, 7:e438-40. 10.1016/S2352-3026(20)30145-9", "volume": "7", "year": "2020" }, { "DOI": "10.1111/jth.14768", "article-title": "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia", "author": "Tang N", "doi-asserted-by": "publisher", "journal-title": "J Thromb Haemost", "key": "ref21", "unstructured": "Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020, 18:844-7. 10.1111/jth.14768", "volume": "18", "year": "2020" }, { "DOI": "10.1056/NEJMoa2028436", "article-title": "Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults", "author": "Anderson EJ", "doi-asserted-by": "publisher", "journal-title": "N Engl J Med", "key": "ref22", "unstructured": "Anderson EJ, Rouphael NG, Widge AT, et al.. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020, 383:2427-38. 10.1056/NEJMoa2028436", "volume": "383", "year": "2020" }, { "DOI": "10.1056/NEJMoa2101765", "article-title": "BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting", "author": "Dagan N", "doi-asserted-by": "publisher", "journal-title": "N Engl J Med", "key": "ref23", "unstructured": "Dagan N, Barda N, Kepten E, et al.. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021, 384:1412-23. 10.1056/NEJMoa2101765", "volume": "384", "year": "2021" }, { "DOI": "10.1093/cid/ciaa1548", "article-title": "Convalescent plasma for patients with severe COVID-19: a matched cohort study", "author": "Rogers R", "doi-asserted-by": "publisher", "journal-title": "Clin Infect Dis", "key": "ref24", "unstructured": "Rogers R, Shehadeh F, Mylona EK, et al.. Convalescent plasma for patients with severe COVID-19: a matched cohort study. Clin Infect Dis. 2020, ciaa1548. 10.1093/cid/ciaa1548", "year": "2020" }, { "DOI": "10.1073/pnas.2004168117", "article-title": "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", "author": "Duan K", "doi-asserted-by": "publisher", "journal-title": "Proc Natl Acad Sci U S A", "key": "ref25", "unstructured": "Duan K, Liu B, Li C, et al.. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020, 117:9490-6. 10.1073/pnas.2004168117", "volume": "117", "year": "2020" }, { "DOI": "10.1056/NEJMoa2031893", "article-title": "Convalescent plasma antibody levels and the risk of death from Covid-19", "author": "Joyner MJ", "doi-asserted-by": "publisher", "journal-title": "N Engl J Med", "key": "ref26", "unstructured": "Joyner MJ, Carter RE, Senefeld JW, et al.. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021, 384:1015-27. 10.1056/NEJMoa2031893", "volume": "384", "year": "2021" }, { "DOI": "10.1038/s41586-020-2349-y", "article-title": "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody", "author": "Pinto D", "doi-asserted-by": "publisher", "journal-title": "Nature", "key": "ref27", "unstructured": "Pinto D, Park YJ, Beltramello M, et al.. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020, 583:290-5. 10.1038/s41586-020-2349-y", "volume": "583", "year": "2020" }, { "DOI": "10.1001/jama.2020.10245", "article-title": "Monoclonal antibodies for prevention and treatment of COVID-19", "author": "Marovich M", "doi-asserted-by": "publisher", "journal-title": "JAMA", "key": "ref28", "unstructured": "Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020, 324:131-2. 10.1001/jama.2020.10245", "volume": "324", "year": "2020" }, { "key": "ref29", "unstructured": "U.S. Food and Drug Administration. Coronavirus (COVID-19) update. FDA authorizes monoclonal antibody for treatment of COVID-19. (2020). Accessed: November 10, 2020: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-tr...." }, { "key": "ref30", "unstructured": "U.S. Food and Drug Administration. Coronavirus (COVID-19) update. FDA authorizes monoclonal antibody for treatment of COVID-19. (2021). Accessed: April 17, 2021: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorizati...." } ], "reference-count": 30, "references-count": 30, "relation": {}, "resource": { "primary": { "URL": "https://www.cureus.com/articles/58640-clinical-impact-of-the-early-use-of-monoclonal-antibody-ly-cov555-bamlanivimab-on-mortality-and-hospitalization-among-elderly-nursing-home-patients-a-multicenter-retrospective-study" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Aerospace Engineering" ], "subtitle": [], "title": "Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study", "type": "journal-article" }